CJC-1295is a synthetic analog of growth hormone releasing hormone (GHRH) — the hypothalamic signal that tells your pituitary to release a GH pulse. It doesn’t add GH from the outside; it pushes the pituitary harder. That distinction determines who benefits and who doesn’t, and it’s why understanding the pituitary ceiling matters before you buy a vial.
What it is
CJC-1295 is a GHRH analog that binds GHRH receptors on pituitary somatotrophs and triggers a GH pulse. The most important thing to know before anything else is the DAC distinction.
CJC-1295 no-DAC(also called Modified GRF 1-29 or Mod GRF) has a short half-life of roughly 15–30 minutes. It produces a sharp, discrete GH pulse timed to the injection. You inject it before bed or pre-workout; the pulse hits and fades. This is the version used in the pre-blended CJC-1295 + Ipamorelin vial.
CJC-1295 with DAC (Drug Affinity Complex) binds to circulating albumin after injection, which extends its active life to approximately 8 days. One injection per week produces sustained, around-the-clock GH elevation rather than discrete timed pulses. The trade-off is less control over when the GH peaks occur; the benefit is convenience.
What the research actually shows
The mechanism story is well-supported: GHRH receptor agonism drives pulsatile GH secretion, and CJC-1295 activates that receptor. The practical ceiling is the pituitary itself. Secretagogues amplify what your pituitary can already produce — they don’t bypass it. Younger users with a responsive pituitary can see meaningful GH pulse amplification. Older users, whose GH pulses have declined roughly 85% from puberty peak by age 55, will find the pituitary increasingly unable to respond to secretagogue stimulus no matter how well the compound is dosed.
There are no large human RCTs on CJC-1295 specifically for body composition. The with-DAC version has pharmacokinetic data supporting once-weekly dosing. Most of the practical protocol guidance comes from clinical use of GHRH analogs broadly and community experience with the no-DAC form.
How people dose it
Standard reconstitution: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL (5,000 mcg/mL). Injection is subcutaneous only — not intramuscular.
No-DAC CJC-1295 (Mod GRF 1-29):
- Low: 150 mcg per injection (3 units on a U-100 syringe), once daily
- Medium: 250–300 mcg per injection (5–6 units), once or twice daily
- High: 300 mcg per injection (6 units), up to three times daily
With-DAC CJC-1295:
- Low: 1 mg once weekly (20 units)
- Medium/High: 1–2 mg once weekly (20–40 units)
Injection must be fasted — no food for at least 2–3 hours beforehand. Elevated insulin raises somatostatin levels, which blunts GH release even when the GHRH receptor is activated. Pre-workout (exercise amplifies the GH pulse) or pre-sleep (the largest natural GH pulse occurs during deep sleep) are the two best windows for no-DAC. With-DAC timing is less critical given the 8-day active window.
Monitor fasted blood glucose weekly while running CJC-1295. GH secretagogues can raise fasting glucose. If it climbs, Berberine (500–2,000 mg/day) is the preferred first-line tool — unlike Metformin, it doesn’t meaningfully suppress IGF-1.
What it stacks well with
The canonical pairing is Ipamorelin. CJC-1295 hits the GHRH receptor; Ipamorelin hits the ghrelin receptor (GHS-R1a). Activating both arms of the GH axis simultaneously produces a substantially larger pulse than either compound alone. This dual-receptor logic is exactly why the CJC-1295 + Ipamorelin blendbecame the most widely used injectable GH secretagogue protocol. If you’re buying CJC and Ipamorelin separately and want to save yourself a vial, the pre-blended option handles both in one injection.
DPP-4 inhibitors (Januvia, Jardiance, linagliptin) inhibit the enzyme that degrades GHRH analogs and related peptides, potentially extending CJC-1295 no-DAC’s active window and amplifying its GH effect. Worth knowing if you’re already on one of those medications.
The honest caveats
- WADA prohibited. GHRH analogs are on the prohibited list. If you compete in a tested sport, this disqualifies.
- FDA Section 503a restricted.CJC-1295 appears on the restricted compound list — not available through US compounding pharmacies by prescription.
- Pituitary rate-limit is real.The older you are, the lower the ceiling. Most users realistically see 1–2 IU equivalent GH output from an optimized secretagogue stack. For doses beyond that ceiling, the next step is exogenous HGH, not more secretagogue.
- Cancer history. Like all GH secretagogues, CJC-1295 promotes IGF-1 signaling downstream of GH. If you have any cancer history, this is a real concern.
- No standard workplace or military drug screens.These tests don’t detect peptides; the risk is sport-specific.
The bottom line
CJC-1295 is the most widely used injectable GHRH analog because the two versions cover opposite ends of the convenience-control spectrum: no-DAC gives you precise timed pulses for the pre-workout and pre-sleep windows; with-DAC gives you one injection a week and sustained elevation in between. For most people starting with injectable GH secretagogues, the no-DAC version stacked with Ipamorelin is the right entry point — dual-receptor coverage, well-established protocol, and enough flexibility to adjust timing around training.
For the math, use the CJC-1295 reconstitution calculator. For the comparison with other GH secretagogues, read the GH secretagogues post. For dosing, refer to the free Peptide Guide.